Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2019; 25(11): 1289-1306
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1289
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1289
Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma
Sang Mi Lee, Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea
Hong Soo Kim, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea
Sangheun Lee, Division of Hepatology, Department of Internal medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Sangheun Lee, Institute for Health and Life Science, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Jeong Won Lee, Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review, drafting, revision, editing of the paper, and approval of the final version.
Supported by the Soonchunhyang University Research Fund .
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jeong Won Lee, MD, PhD, Associate Professor, Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, 25, Simgok-ro 100 beon-gil, Seo-gu, Incheon 22711, South Korea. jwlee223@ish.ac.kr
Telephone: +82-32-2902975 Fax: +82-32-2903128
Received: January 24, 2019
Peer-review started: January 24, 2019
First decision: February 21, 2019
Revised: February 25, 2019
Accepted: March 1, 2019
Article in press: March 1, 2019
Published online: March 21, 2019
Processing time: 55 Days and 4.7 Hours
Peer-review started: January 24, 2019
First decision: February 21, 2019
Revised: February 25, 2019
Accepted: March 1, 2019
Article in press: March 1, 2019
Published online: March 21, 2019
Processing time: 55 Days and 4.7 Hours
Core Tip
Core tip: Because of low sensitivity, clinical use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been limited in patients with hepatocellular carcinoma (HCC). However, recent studies have shown clinical significance of FDG PET in various ways. The objective of this review is to provide an overview of the current literature regarding FDG PET in HCC and discuss emerging role of FDG PET in aiding management of HCC patients.